An Update On Primary Findings and New Designs in Biotherapy Studies for Acute Myocardial Infarction

ABSTRACT 

Treatment of acute myocardial infarction in the future should focus not only on improving acute treatment, as it has been done over the past decades, but also on secondary prevention of left ventricular dysfunction and/or progression to heart failure by preserving left ventricular shape, avoiding left ventricular remodeling and stimulating cardiac regeneration. Biotherapies with adult stem cells and bone marrow-derived endothelial cell progenitors, combined or not with biomaterials, and new drugs are under investigation and will probably be part of routine clinical practice for patients suffering from myocardial infarction in the near future.

KEYWORDS :

• alginates
• biomaterials
• cardiac regeneration
• cardioprotection
• mesenchymal stromal cells
• CD34⁺ cells
• left ventricular remodeling
• mononucleated cells

Financial & competing interests disclosure

J Roncalli has received consultant fees and/or honoraria from Medtronic, Ikaria, Cellprothera. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.